Breast Cancer Liquid Biopsy Market

A tumour can be sampled from a vein instead of an operating theatre, and a test that can be repeated every few weeks tells an oncologist things a single biopsy never could. Douglas Insights values the breast cancer liquid biopsy market at USD 1.33 billion in 2025 and expects USD 4.21 billion by 2035, compounding at 12.24%. The estimate is built from the bottom up: roughly 1.7 million breast cancer liquid biopsy tests performed in 2025 across therapy selection and companion diagnostics, treatment monitoring and molecular residual disease detection, early detection and screening, and circulating tumour cell, exosome and research use (all cancers are covered in our Circulating Tumor Cell Diagnostics Market report), at an average realised price of USD 780 per test, triangulated against breast cancer incidence and prevalence, test volumes and laboratory disclosures. Tests grow 15.0% a year as targeted therapies requiring blood based mutation testing expand and monitoring gains coverage, while price per test falls 2.4% a year as sequencing costs decline and competition increases; the cell-free DNA extraction behind each test is sized in our Magnetic Bead-based Nucleic Acid Extraction Market report. Tissue biopsy devices are covered in a separate report and excluded here. This study sits within our in vitro diagnostics coverage and follows the published Douglas Insights methodology.

Why did a blood test become necessary for breast cancer treatment?

Because new targeted drugs for advanced breast cancer work only in patients whose tumours carry specific mutations, and some of those mutations appear during treatment and are best detected in a blood sample. Liquid biopsy analyses fragments of tumour DNA circulating in the blood, known as circulating tumour DNA, avoiding the need for a new tissue biopsy. In hormone receptor positive breast cancer, the most common type, mutations in the ESR1 gene often emerge after patients have been treated with hormone therapy, making their cancer resistant. Drugs that target ESR1 mutated cancer have been approved together with blood based companion diagnostic tests that identify eligible patients, and other targeted therapies acting on the PIK3CA, AKT1 and PTEN pathways also depend on mutation testing. Because these mutations can arise during treatment, repeated testing from blood is more practical than repeated tissue biopsies. This has made liquid biopsy a routine part of treatment decisions for advanced breast cancer in many centres. The exclusive chapter of this report tracks targeted therapy approvals and their testing requirements, since each new therapy expands test volumes.

What does this market include?

This study covers blood based tests that detect or analyse breast cancer from circulating tumour DNA, circulating tumour cells and other circulating markers. Therapy selection and companion diagnostics cover tests that identify mutations guiding treatment choices, including companion diagnostics approved with specific drugs. Treatment monitoring and molecular residual disease cover tests that track response to treatment and detect traces of cancer remaining after surgery or signalling recurrence. Early detection and screening cover blood tests aimed at detecting breast cancer, including multi cancer early detection tests, before symptoms. Circulating tumour cell, exosome and research use cover other circulating biomarker tests and research applications. Tissue biopsy devices, covered in our separate biopsy devices coverage, tissue based genomic tests, mammography and imaging, and germline hereditary cancer testing sit outside the boundary. Value is measured at laboratory test revenue.

Could blood tests detect recurrence earlier?

Yes, and this is the most promising area of growth, though evidence on how best to use it is still developing. After surgery and treatment for early breast cancer, some patients relapse because microscopic disease remains. Molecular residual disease tests, which look for tiny amounts of tumour DNA in blood using assays personalised to each patient’s tumour, can detect this remaining disease months before recurrence becomes visible on scans. This could allow earlier intervention, or reassure patients whose tests are negative. Such tests are available and increasingly covered by some insurers, and clinical trials are testing whether acting on a positive result improves survival. The key open question is whether earlier detection translates into better outcomes, and until trials answer it, use will grow gradually rather than becoming universal. The model treats monitoring and residual disease testing as a fast growing category whose pace depends on trial results and reimbursement.

What drives demand?

The first driver is targeted therapies. New drugs for advanced breast cancer that require mutation testing expand the number of patients tested, often repeatedly.

The second driver is treatment monitoring. Molecular residual disease and response monitoring tests are gaining clinical adoption and coverage.

The third driver is patient convenience. Blood tests avoid invasive tissue biopsies and can be repeated easily, which patients and doctors prefer.

The fourth driver is falling sequencing costs. Cheaper sequencing makes liquid biopsy more affordable and supports wider use.

What restrains the market?

Three restraints are modelled. Reimbursement is the first: coverage for liquid biopsy, especially for monitoring and screening, varies widely and limits use. Sensitivity limits are second: blood tests can miss cancer that sheds little DNA, particularly in early stage disease, so tissue testing remains needed in some cases and screening performance for early breast cancer is limited. Evidence gaps are third: for monitoring and screening, clinical utility evidence is still being established, which slows guideline adoption.

Which applications carry the value?

Therapy selection and companion diagnostics lead with 44% of 2025 value, USD 583.4 million, driven by targeted therapies for advanced breast cancer. Treatment monitoring and molecular residual disease hold 30%, USD 397.8 million, and grow fastest. Circulating tumour cell, exosome and research use accounts for 14%, USD 185.7 million, and early detection and screening 12%, USD 159.1 million, the latter held back by limited sensitivity for early breast cancer and the dominance of mammography. Each application is modelled through 2035 by region.

Where are breast cancer liquid biopsies performed?

North America leads with 56% of 2025 value, USD 742.6 million, growing 11.28% a year, reflecting early adoption, approvals of companion diagnostics and higher test prices. Europe holds 22%, USD 291.7 million, at 12.2%, with adoption rising as reimbursement expands. Asia Pacific holds 17%, USD 225.4 million, and grows fastest at 15.0%, driven by large patient populations in China and expanding access in Japan, South Korea and elsewhere. Latin America contributes USD 33.2 million at 12.0%, the Middle East USD 23.9 million at 13.0% and Africa USD 9.3 million at 11.0%. Six regional models sum to the global figure, with country tables in the Excel model.

Who provides breast cancer liquid biopsy?

Guardant Health and Foundation Medicine, part of Roche, provide widely used comprehensive liquid biopsy tests, including companion diagnostics for breast cancer therapies. Natera provides personalised molecular residual disease testing, and other companies including Exact Sciences and Invitae offer related tests. Grail develops multi cancer early detection. Qiagen, Thermo Fisher and Illumina supply technologies used by laboratories, and Menarini Silicon Biosystems supplies circulating tumour cell technology. Chinese companies provide tests in their domestic market. The competitive chapter profiles each provider’s tests, approvals, coverage and regional presence.

How are these tests priced?

Average realised price is USD 780 per test in 2025, varying widely. Comprehensive genomic profiling tests for therapy selection typically carry list prices of several thousand dollars in the United States, though realised payment is lower, while targeted mutation tests cost less and monitoring tests are priced per draw within ongoing programmes. Prices are much lower in many markets outside the United States. Falling sequencing costs and competition push prices down, which is the reason for the negative price leg. The pricing chapter publishes price bands by application and region.

How do the scenarios diverge by 2035?

The base case carries 15.0% growth in tests and a 2.4% annual price decline for a 12.24% revenue CAGR and USD 4,207.7 million in 2035. The reimbursement-limited scenario, in which coverage for monitoring stays restricted and price pressure intensifies, sets the legs at 9.0% and minus 4.0%, landing near USD 2,120 million. The monitoring-standard scenario, in which trials show clear benefit from acting on residual disease results and monitoring becomes routine, sets them at 19.0% and minus 1.4%, carrying the market past USD 6,470 million. Each 1-point change in test growth moves the 2035 figure by roughly USD 370 million.

Which rules and standards apply?

Three layers matter. In vitro diagnostic regulation comes first: companion diagnostics require regulatory approval alongside the drugs they accompany, and laboratory developed tests are subject to laboratory regulation and evolving oversight. Reimbursement and coverage are second: decisions by public and private payers on which tests and indications to cover largely determine volumes. Clinical guidelines are third: inclusion of liquid biopsy in oncology treatment guidelines drives adoption. The regulatory chapter maps these requirements by jurisdiction.

Will blood tests replace mammography for screening?

Not within this forecast. Mammography remains the established screening tool for breast cancer, backed by decades of evidence and organised screening programmes. Current blood tests detect early stage breast cancer less reliably than they detect advanced cancer, because small early tumours shed little DNA into the blood, so their sensitivity for early breast cancer is limited. Multi cancer early detection tests may add value by detecting cancers that have no screening programme, but they are not a substitute for mammography. The model therefore treats screening as a small, slower growing category and expects liquid biopsy growth to come mainly from treatment selection and monitoring.

Douglas Exclusive: the targeted therapy and testing tracker

This report tracks, by drug and region, approvals of breast cancer targeted therapies, the biomarkers and tests they require, patient populations, testing frequency and reimbursement, converting treatment patterns into test volumes and revenue by application and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from tests: breast cancer incidence and prevalence by stage and subtype, testing rates for therapy selection and monitoring, testing frequency, reimbursement, and realised prices from laboratory disclosures, with tissue biopsy devices, tissue genomic tests, imaging and germline testing excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.